Kerri Fitzgerald

DocwireNews

Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, plus nab-paclitaxel showed promising anti-tumor activity in patients with HER2-positive advanced or metastatic breast cancer. The results were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
The multicenter, single-arm, open-label, phase 2 study was conducted in China and included women aged 18 to 75 years with histologically or cytologically confirmed HER2-positive advanced or metastatic breast cancer. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, and those with primary resistance to trastuzumab and bone-only metastases were excluded from the study.
A total of 51 patients were enrolled between December 2019 and December 2021. Median patient age was 55 years (range, 35-72 years), and 23 patients (45.1%) had an ECOG score of 0. Of the total number of patients, 10 (19.6%) with metastatic disease had previously received first-line treatment, and 28 (54.9%) had received prior treatment with trastuzumab. More than half of the patients (n=29; 56.9%) had hormone receptor-positive disease. Visceral metastases occurred in 56.9% of the patients (n=29), and 26 patients (51%) were menopausal.
Patients received pyrotinib 400 mg orally daily plus nab-paclitaxel 125 mg/m2 intravenously on days 1, 8, and 15 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal, or death.
As of January 21, 2022 (data cutoff), 38 patients were evaluable. The confirmed objective response rate (primary endpoint) was 81.6% (95% CI, 65.1-91.7). Responses to treatment included: complete response in 4 patients (10.5%), partial response in 27 patients (71.1%), stable disease in 6 patients (15.8%), and progressive disease in 1 patient (2.6%). Progression-free survival data were still immature at the time of reporting.
Among the full cohort, the most common grade ≥3 treatment-emergent adverse events were neutropenia (n=14; 27.5%), diarrhea (n=10; 19.6%), fatigue (n=5; 9.8%), and peripheral neuropathy (n=4; 7.8%).
Reference
Li H, Li Z, Yan M, et al. Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial. <a href="https://meetings.asco.org/abstracts-presentations/210465">Abstract #1035</a>. Presented at the 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022; Chicago, IL.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer

ASCO 2022

Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, plus nab-paclitaxel showed promising anti-tumor ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe